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DOI 10.1016/j.stem.2011.08.002Unfertilized oocytes of many mammalian
species can reprogram somatic cells to
a pluripotent state. Human oocytes might
therefore be useful for producing patient-
derived pluripotent stem cells. Because
they would carry the patient’s genotype,
these stem cells may be useful for the
production of autologous transplants.
Such cells could also be used to deter-
mine whether the epigenetic (Lister
et al., 2011) and genetic (Gore et al.,
2011) changes detected in induced
pluripotent stem cells (iPSCs) are univer-
sally found in reprogrammed cell lines or
instead are unique to iPSCs. In addition
to their importance for the study of re-
programming and nuclear transplanta-
tion, human oocytes have significant
utility for research aimed at the establish-
ment of new infertility treatments. There-
fore, there is ample scientific rationale for
the use of oocytes in research. However,
due to the unresolved ethical and political
debate surrounding nuclear transfer and
stem cell biology, it has been difficult for
institutions to determine how best to
responsibly proceed with research that
depends on the availability of high-quality
oocytes. In an attempt to resolve this
uncertainty, the National Academy of
Science (NAS) published guidelines that
suggested that for stem cell research,
only altruistic egg donors willing to partic-
ipate without compensation should be
recruited (National Research Council,
2005).
Due to our interest in nuclear transfer,
we developed research protocols for
oocyte donation that were consistent
with both NAS stem cell guidelines andapplicable state laws. These protocols
were approved by the participating aca-
demic institutions’ committees on the
useof humansubjects in research, by their
stem cell research oversight committees,
and by the Western Institutional Review
Board, an Associate of the Accreditation
of Human Research Protection Programs.
With IRB approval, from May 2006 to
March 2007, we advertised extensively
for our study, attempting to recruit al-
truistic women willing to undergo hor-
mone-induced superovulation followed
by surgical egg retrieval in exchange for
reimbursement of only their direct ex-
penses. To attract attention to our study,
we advertised in area newspapers and
magazines, and on public transportation
and the Internet. Initial response rates
were high, with 239 potential donors
contacting our study coordinator. One-
hundred and sixty-eight of these women
answeredall questions regardingeligibility
for the study and seventy-nine met all
study criteria, including age (25–35),
normal menstruation, and other indicators
of goodhealth.However, only oneof these
women entered the protocol. Following
hormone-controlled superovulation, six
oocytes were surgically retrieved from
this woman and utilized for an unsuccess-
ful attempt at nuclear transfer.
Because we could not recruit enough
egg donors to enable controlled nuclear
transfer experiments, we sought to better
understand why women were not en-
rolling in our study. With IRB approval,
we recorded each of the concerns raised
by 52 qualified, prospective donors dur-
ing their conversations with our studyCell Stem Cellcoordinator. The absence of financial
compensation was mentioned most
frequently (25 times), followed closely by
the medical procedures involved (18
times, including medications, injections,
surgery, and potential side effects). The
significant amount of time required for
participation was also commonly raised
(17 times). Hesitation to participate in
stem cell research was not mentioned
by prospective donors as a potential rea-
son for opting out of our study. Because
constraints on recruitment imposed by
the NAS guidelines and state law did not
allow us to address concerns raised by
potential donors, we closed our research
protocol in October 2008. In summary,
it was our experience that it is impractical
to recruit ‘‘altruistic’’ oocyte donors and
it suggests that investigators located
in states or countries that limit compen-
sation for egg donation are likely to
encounter similar difficulties.
Oocyte donation for assisted reproduc-
tion is an established part of clinical prac-
tice at in vitro fertilization (IVF) clinics. In
this context, oocyte donors typically re-
ceive compensation of between $5000
and $8000 (Ethics Committee of the
American Society for Reproductive Medi-
cine, 2007). A recent study has shown
that a majority of oocyte donors believe
that similar compensation should also be
provided regardless of whether the result-
ing oocytes are used for research or as-
sisted reproduction (Klitzman and Sauer,
2009).
The International Society for Stem Cell
Research (ISSCR) (Daley et al., 2007) and
the Ethics Committee of the American9, October 7, 2011 ª2011 Elsevier Inc. 293
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(ASRM) (2007) have recently published
guidelines that allow remuneration for
research oocyte donation. Under these
frameworks, remuneration could be
provided in the form of direct compensa-
tion to women undergoing oocyte re-
trieval for the sole purpose of providing
oocytes to research. Alternatively, ar-
rangements could be made whereby
part of the costs for the donor’s own IVF
treatments are covered by research funds
in exchange for donation of a fraction of
the resulting oocytes, so called egg
sharing. The Human Fertilisation and
Embryology Authority (HFEA) have also
considered the possibility of compen-
sating egg donors in the UK, and although
they fell short of recommending direct
compensation, they did opt to allow egg
sharing (HFEA, 2007).
Importantly, preliminary results suggest
that compensating donors for their time
and effort would increase the number of
women willing to participate in egg dona-
tion for research (Cibelli et al., 2002).
Furthermore, direct compensation has
now been successfully employed to
obtain oocytes for nuclear transfer that
had demonstrated utility in reprogram-
ming (Noggle et al., 2011).294 Cell Stem Cell 9, October 7, 2011 ª2011Both ASRM and ISSCR guidelines state
that financial considerations should not
result in an undue inducement for women
to participate in egg donation. We firmly
agree that compensation for egg donors
must be limited to sums that do not tempt
women to discount the physical and
emotional risks of the procedure they are
considering. However, we believe that if
payments for research oocyte donation
are contingent on the approval of appro-
priate oversight committees, and that if
the health of oocyte donors is carefully
monitored during their participation, the
guidelines approved by HFEA, ASRM,
and ISSCR, as well as those proposed in
a recent position paper (Hyun, 2011),
should protect donor safety. We propose
that if any of these newer guidelines were
morewidely adopted by academic institu-
tions and funding agencies, it could signif-
icantly accelerate stem cell research and
progress toward novel IVF treatments
while still protecting the safety of donors.
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